CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser

Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser

MARKN.

CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that the company intends to change Certified Adviser from FNCA Sweden AB to Västra Hamnen Corporate Finance AB.

CombiGene, listed on Nasdaq First North Growth Market, has signed an agreement with Västra Hamnen Corporate Finance AB for the service as Certified Adviser on Nasdaq First North Growth Market. Västra Hamnen will be the company's Certified Adviser from August 25, 2024.

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Sign up here to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.

Datum	2024-06-14, kl 15:00
Källa	MFN

Bifogade filer

CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser

LOGGA IN

Lärkberget

CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser